Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:2012:704872.
doi: 10.1155/2012/704872. Epub 2012 Mar 18.

A meta-analysis of osteosarcoma outcomes in the modern medical era

Daniel C Allison  1 , Scott C Carney, Elke R Ahlmann, Andrew Hendifar, Sant Chawla, Alex Fedenko, Constance Angeles, Lawrence R Menendez
Affiliations

A meta-analysis of osteosarcoma outcomes in the modern medical era

Daniel C Allison et al. Sarcoma. 2012.

Abstract

Four decades ago, specialized chemotherapy regimens turned osteosarcoma, once considered a uniformly fatal disease, into a disease in which a majority of patients survive. Though significant survival gains were made from the 1960s to the 1980s, further outcome improvements appear to have plateaued. This study aims to comprehensively review all significant, published data regarding osteosarcoma and outcome in the modern medical era in order to gauge treatment progress. Our results indicate that published survival improved dramatically from 1960s to 1980s and then leveled, or in some measures decreased. Recurrence rates decreased in the 1970s and then leveled. In contrast, published limb salvage rates have increased significantly every recent decade until the present. Though significant gains have been made in the past, no improvement in published osteosarcoma survival has been seen since 1980, highlighting the importance of a new strategy in the systemic management of this still very lethal condition.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Osteosarcoma 5-year overall survival.
Figure 2
Figure 2
Osteosarcoma 10-year overall survival.
Figure 3
Figure 3
Osteosarcoma 3-year disease-free survival.
Figure 4
Figure 4
Osteosarcoma 5-year disease-free durvival.
Figure 5
Figure 5
Osteosarcoma 10-year disease-free survival.
Figure 6
Figure 6
Osteosarcoma recurrence rates.
Figure 7
Figure 7
Osteosarcoma limb salvage rates.
Figure 8
Figure 8
Metastatic osteosarcoma 5-year overall survival.
Figure 9
Figure 9
Pelvic osteosarcoma 5-year overall survival.
Figure 10
Figure 10
Osteosarcoma 5-year overall survival among limb salvage cases.
See this image and copyright information in PMC

References

    1. Coventry MB, Dahlin DC. Osteogenic sarcoma: a critical analysis of 430 cases. The Journal of Bone and Joint Surgery. 1957;39(4):741–758. - PubMed
    1. Rosen G. Preoperative (neoadjuvant) chemotherapy for osteogenic sarcoma: a ten year experience. Orthopedics. 1985;8(5):659–664. - PubMed
    1. Anninga JK, Gelderblom H, Fiocco M, et al. Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? European Journal of Cancer. 2011;47(16):2431–2445. - PubMed
    1. Carter SK. The dilemma of adjuvant chemotherapy for osteogenic sarcoma. Cancer Clinical Trials. 1980;3(1):29–36. - PubMed
    1. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. Journal of Clinical Oncology. 1994;12(2):423–431. - PubMed

LinkOut - more resources